Blanca Bisuna, MD
Family Medicine · San Luis Obispo, CANPI 1508199431
Payments from drug & device makers
Across 395 payments — averaging $22.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Lilly USA, LLC$1K
- Novo Nordisk$960
- AbbVie$875
- Pfizer$484
- GSK$368
- plus $3K from 28 others
What the payments were for
- Consulting fees$250%
- Food & beverage$8,97799%
- Education$551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 60 | $2,189 |
| Lilly USA, LLC | 76 | $1,333 |
| Novo Nordisk | 43 | $960 |
| AbbVie(2 entities) | 43 | $875 |
| Pfizer | 33 | $484 |
| GSK | 16 | $368 |
| Boehringer Ingelheim | 10 | $232 |
| Merck | 9 | $227 |
| Adlon Therapeutics L.p. | 14 | $220 |
| Novartis | 6 | $219 |
| Abbott | 11 | $211 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $189 |
| Medtronic(2 entities) | 3 | $181 |
| Sanofi | 7 | $174 |
| Johnson & Johnson | 4 | $170 |
| Amarin Pharma, Inc. | 11 | $162 |
| Boston Scientific | 1 | $139 |
| Biohaven Pharmaceuticals, Inc. | 3 | $115 |
| Amgen(2 entities) | 5 | $80 |
| Bayer | 4 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $61 |
| Edwards Lifesciences | 2 | $57 |
| Exact Sciences | 2 | $42 |
| Daiichi Sankyo Inc. | 3 | $42 |
| Idorsia Pharmaceuticals US Inc | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| Antares Pharma, Inc. | 2 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Inari Medical, Inc. | 1 | $28 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| IBSA Pharma Inc. | 1 | $24 |
| Shire North American Group Inc | 1 | $16 |
| Eisai Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,057 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 76 | $83,403 |
| OzempicSemaglutide | 31 | $57,858 |
| MounjaroTirzepatide | 27 | $44,136 |
| EliquisApixaban | 43 | $42,862 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $39,778 |
| Xigduo XrDapaglifloz Propaned/Metformin | 32 | $29,665 |
| RybelsusSemaglutide | 15 | $29,599 |
| ProliaDenosumab | 12 | $20,166 |
| TrulicityDulaglutide | 15 | $20,050 |
| PremarinEstrogens, Conjugated | 29 | $16,000 |
| JardianceEmpagliflozin | 11 | $14,791 |
| MyrbetriqMirabegron | 15 | $13,714 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $11,199 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $9,382 |
| JanuviaSitagliptin Phosphate | 13 | $7,916 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $960 | $87,45746 claims |
| AstraZenecaFarxiga | $2,189 | $83,40376 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,333 | $64,18642 claims |
| PfizerEliquis, Premarin | $484 | $58,86272 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $368 | $49,16044 claims |
| AmgenProlia | $80 | $20,16612 claims |
| Boehringer IngelheimJardiance | $232 | $14,79111 claims |
| MerckJanuvia | $227 | $7,91613 claims |
| AbbVieSynthroid | $875 | $3,75842 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in San Luis Obispo
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.